Researchers identify novel SARS-CoV-2 variant with mutations in membrane protein-encoding gene

A recent study published in the Journal Emerging Microbes and Infections has highlighted the emergence of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant with mutations in the membrane protein-encoding gene. Two potential mutations, M:I82T and M:V70L, have been identified within the transmembrane helices, which are expected to improve viral fitness by modulating glucose uptake during replication.

Background

Whole-genome sequencing studies of newly emerging viral variants are particularly important for identifying mutations that emerge under positive selection and play vital roles in viral evolution. In the later phase of the coronavirus disease 2019 (COVID-19) pandemic, several novel SARS-CoV-2 variants with multiple spike protein mutations have emerged. Because of significantly increased infectivity and immune escape ability, some of these variants have become the predominantly circulating variants worldwide. Therefore, to effectively control the trajectory of COVID-19 pandemic, continuous genomic surveillance of SARS-CoV-2 sequences both at the national- and global level are of prime importance.

In the current study, scientists have reported the emergence of a novel SARS-CoV-2 variant containing signature mutations in the membrane protein-encoding gene.

Study design

The scientists conducted reverse transcription-polymerase chain reaction (RT-PCR) for whole-genome sequencing of a total of 2,900 SARS-CoV-2-positive patient samples. They subsequently compared these sequences with full-length SARS-CoV-2 sequences downloaded from the GISAID and NCBI databases for viral variant analysis.

Furthermore, they performed phylogenetic analysis and SARS-CoV-2 membrane protein structural predictions using a multiple sequence alignment program and a specialized service for structural analysis of missense variants.      

Important observations

By analyzing the missense mutation carrying genome and synonymous mutation carrying genome, the scientists estimated that missense mutations should occur 2.7 times, 3.1 times, 3.8 times more frequently than the synonymous mutations in the envelope protein-coding gene, membrane protein-coding gene, and ORF6-coding gene, respectively. By comparing missense mutation carrying genomes with synonymous mutation carrying genomes, they noticed that the membrane gene is highly conserved and possibly under robust purifying selection.

By estimating the membrane gene missense mutation carrying viral genomes, they identified only 4 missense mutations in viral genomes collected from the USA in February 2021. With further analysis, they observed a gradual increase in missense membrane gene mutations in viral genomes in the USA and worldwide.

Phylogenetic analysis of viral genomes carrying missense M mutations, colored by lineage background.
Phylogenetic analysis of viral genomes carrying missense M mutations, colored by lineage background.

By analyzing the frequency of increase for these mutations, they observed that M:I48V mutation is highly specific to the USA and that most of the viral isolates carrying this mutation belong to the B.1.375 lineage. However, currently, the frequency of this mutation dropped significantly in the USA.     

In contrast to the M:I48V mutation, the frequency of M:I82T mutation was found to increase by 116-fold between October 2020 and February 2021 in the USA. The scientists confirmed that the viral isolates carrying this mutation predominantly belong to the B.1 and B.1.525 lineages and that about 99% of the B.1.525 lineage currently carry this mutation.

With further analysis, the scientists noticed that the largest M:I82T carrying clade is part of a young M:I82T sub-B.1 lineage and that about 90% of the isolates in this clade contain 10 other missense mutations. They mentioned that the M:I82T clade is significantly different from other B.1 lineage clades, and thus, a separate designation is required for this clade. Interestingly, they found that the second-largest M:I82T carrying clade is currently circulating in Europe and Africa and co-segregating with the E484K Spike protein mutation. Because of the absence of E484K Spike mutation in the USA M:I82T clade, the scientists suggest that M:I82T mutation may have implications in viral evolution independent of E484K Spike mutation.          

The scientists identified a number of other membrane gene mutations that showed a recent surge in frequency worldwide. Focusing on these mutations, they collected more than 5,500 sequences carrying any of these mutations for phylogenetic analysis. Their analysis revealed that many of these sequences belong to the B.1.1.7 lineage, which also carries a synonymous membrane gene mutation.

Furthermore, the scientists selected four membrane gene mutations (M:A2S, M:F28L, M:I82T, and M:V70L) and analyzed their presence in viral isolates collected from the study patients. Their analysis revealed that the mean age of patients carrying each of these mutations was 37 – 39 years, whereas the mean age of patients without these mutations was 43 years.

Study significance

The study highlights the rapid emergence of the B.1.I82T clade with SARS-CoV-2 membrane gene mutations in the USA and worldwide. Overall, the findings suggest that viral variants containing membrane gene mutations exhibit higher transmissibility among younger populations and that mutations emerging in the viral membrane protein-encoding gene play crucial roles in increasing viral fitness probably by controlling glucose uptake during viral replication.

Journal reference:
Dr. Sanchari Sinha Dutta

Written by

Dr. Sanchari Sinha Dutta

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world. She has a Bachelor of Science (B.Sc.) degree and a Master's of Science (M.Sc.) in biology and human physiology. Following her Master's degree, Sanchari went on to study a Ph.D. in human physiology. She has authored more than 10 original research articles, all of which have been published in world renowned international journals.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dutta, Sanchari Sinha Dutta. (2021, May 03). Researchers identify novel SARS-CoV-2 variant with mutations in membrane protein-encoding gene. News-Medical. Retrieved on November 25, 2024 from https://www.news-medical.net/news/20210503/Researchers-identify-novel-SARS-CoV-2-variant-with-mutations-in-membrane-protein-encoding-gene.aspx.

  • MLA

    Dutta, Sanchari Sinha Dutta. "Researchers identify novel SARS-CoV-2 variant with mutations in membrane protein-encoding gene". News-Medical. 25 November 2024. <https://www.news-medical.net/news/20210503/Researchers-identify-novel-SARS-CoV-2-variant-with-mutations-in-membrane-protein-encoding-gene.aspx>.

  • Chicago

    Dutta, Sanchari Sinha Dutta. "Researchers identify novel SARS-CoV-2 variant with mutations in membrane protein-encoding gene". News-Medical. https://www.news-medical.net/news/20210503/Researchers-identify-novel-SARS-CoV-2-variant-with-mutations-in-membrane-protein-encoding-gene.aspx. (accessed November 25, 2024).

  • Harvard

    Dutta, Sanchari Sinha Dutta. 2021. Researchers identify novel SARS-CoV-2 variant with mutations in membrane protein-encoding gene. News-Medical, viewed 25 November 2024, https://www.news-medical.net/news/20210503/Researchers-identify-novel-SARS-CoV-2-variant-with-mutations-in-membrane-protein-encoding-gene.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis